Skip to main content
Caplight Logo









Gate Neurosciences

Gate Neurosciences

Private
Indianapolis, IndianaHealthcare & Life Scienceshttps://syndeio.bio

Last Round

M&A

May 27, 2025

Total Funding Raised

$58.9M

Company Overview

Gate Neurosciences is a biotechnology company that develops precision medicines to treat central nervous system disorders by enhancing synaptic function and neuroplasticity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Mental Health

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologyCNS disordersprecision medicinedrug discoveryNMDA receptor modulatorssynaptic plasticityneuropsychiatric disordersclinical trialsbiomarker analyticsneurotechiPSC modelingquantitative EEGqEEGdigital therapeuticsmental health techbrain health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gate Neurosciences Comparables

Compare Gate Neurosciences with similar companies based on industry and business-model similarity.

Gate Neurosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Otsuka Holdings
81%
Delix Therapeutics
81%
Spinogenix, Inc.
78%

Gate Neurosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMay 27, 2025
Convertible DebtDec 31, 2024
Convertible DebtSep 30, 2022
Convertible DebtNov 24, 2021

Key People

Founding team and executive leadership

Michael G. McCully

Co-Founder, President Chief Operating Officer

Founding Team

Gate Neurosciences Investors

Notable investors and investment history

Gate Neurosciences investors
InvestorRounds
BioCrossroadsConvertible Debt, Seed
Luson BioVenturesConvertible Debt, M&A
InnovivaConvertible Debt, M&A
Catalio Capital ManagementM&A
M CapitalM&A
PagodaTree PartnersM&A
TenmileM&A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2025

    $62M round led by Innoviva and Catalio Capital Management.

  • Dec 31, 2024

    $11M round raised, led by Innoviva.

Gate Neurosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gate Neurosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gate Neurosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersIndianapolis, Indiana
Employee Range1
Year Founded2019
Last FundingMay 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?